CONCLUSIONS
Our study indicated that fruquintinib weekly dose‐escalation strategy during the first cycle maintained its efficacy and its safety profile was tolerable. Physicians may consider this fruquintinib dose‐escalation strategy as a viable alternative to the standard 5 mg/day dosing in the management of elderly patients with refractory mCRC.